The latest price target for Genmab (NASDAQ:GMAB) was reported by Leerink Partners on February 13, 2025. The analyst firm set a price target for $27.00 expecting GMAB to rise to within 12 months (a possible 20.91% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ:GMAB) was provided by Leerink Partners, and Genmab upgraded their outperform rating.

The last upgrade for Genmab AS happened on February 13, 2025 when Leerink Partners raised their price target to $27. Leerink Partners previously had a market perform for Genmab AS.

The last downgrade for Genmab AS happened on August 20, 2024 when JP Morgan changed their price target from N/A to N/A for Genmab AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a upgraded with a price target of $0.00 to $27.00. The current price Genmab (GMAB) is trading at is $22.33, which is within the analyst’s predicted range.